4/18
02:13 pm
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
4/17
04:01 pm
rlyb
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
Medium
Report
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
4/12
12:07 pm
rlyb
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up [Yahoo! Finance]
Medium
Report
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up [Yahoo! Finance]
4/11
10:22 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at Wedbush from $13.00 to $11.00. They now have an "outperform" rating on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at Wedbush from $13.00 to $11.00. They now have an "outperform" rating on the stock.
4/11
07:02 am
rlyb
Rallybio shares gain on investment from J&J for rare fetal condition treatment [Seeking Alpha]
Medium
Report
Rallybio shares gain on investment from J&J for rare fetal condition treatment [Seeking Alpha]
4/10
05:30 pm
rlyb
J&J, Rallybio partner on drug development for rare fetal condition [Yahoo! Finance]
High
Report
J&J, Rallybio partner on drug development for rare fetal condition [Yahoo! Finance]
4/10
04:09 pm
rlyb
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) [Yahoo! Finance]
High
Report
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) [Yahoo! Finance]
4/10
04:01 pm
rlyb
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
High
Report
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
4/1
10:15 am
rlyb
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting [Yahoo! Finance]
4/1
10:05 am
rlyb
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
Low
Report
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
3/18
03:16 pm
rlyb
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at HC Wainwright from $12.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at HC Wainwright from $12.00 to $9.00. They now have a "buy" rating on the stock.
3/18
03:12 pm
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
3/12
08:31 am
rlyb
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/12
08:00 am
rlyb
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
2/26
08:00 am
rlyb
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
Low
Report
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
2/7
11:34 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at JMP Securities from $16.00 to $8.00. They now have a "market outperform" rating on the stock.
Low
Report
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at JMP Securities from $16.00 to $8.00. They now have a "market outperform" rating on the stock.
2/7
08:49 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at Wedbush from $14.00 to $13.00. They now have an "outperform" rating on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at Wedbush from $14.00 to $13.00. They now have an "outperform" rating on the stock.
2/7
08:14 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at HC Wainwright from $17.00 to $12.00. They now have a "buy" rating on the stock.
High
Report
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at HC Wainwright from $17.00 to $12.00. They now have a "buy" rating on the stock.
2/7
07:36 am
rlyb
Rallybio Co. (NASDAQ: RLYB) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $1.50 price target on the stock, down previously from $7.00.
High
Report
Rallybio Co. (NASDAQ: RLYB) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $1.50 price target on the stock, down previously from $7.00.
2/6
10:35 am
rlyb
Rallybio Shares Rally on Portfolio Realignment, Job Cuts [MarketWatch]
Medium
Report
Rallybio Shares Rally on Portfolio Realignment, Job Cuts [MarketWatch]
2/6
08:18 am
rlyb
Rallybio to Cut 45% of Staff in Portfolio Prioritization [MarketWatch]
High
Report
Rallybio to Cut 45% of Staff in Portfolio Prioritization [MarketWatch]
2/6
08:13 am
rlyb
Rallybio Announces Portfolio Prioritization and Provides Corporate Update [Yahoo! Finance]
High
Report
Rallybio Announces Portfolio Prioritization and Provides Corporate Update [Yahoo! Finance]
2/6
08:00 am
rlyb
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
High
Report
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
2/5
08:12 am
rlyb
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors [Yahoo! Finance]
Medium
Report
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors [Yahoo! Finance]
1/29
10:29 am
rlyb
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
Low
Report
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]